Current status of renal denervation in resistant hypertension

Journal of the American Society of Hypertension

Volumn 6, Issue 6, 2012, Pages 414-416

  Ruilope, Luis M ^a   Schmieder, Roland ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

blood pressure; Renal denervation; resistant hypertension

Indexed keywords

ALDOSTERONE; SPIRONOLACTONE;

ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CATHETER; FOLLOW UP; HUMAN; INSULIN RESISTANCE; KIDNEY DENERVATION; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE;

CATHETER ABLATION; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY;

EID: 84870457726     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2012.10.001     Document Type: Review

References (22)

1. D.A. Calhoun, D. Jones, S. Textor, D.C. Goff, T.P. Murphy, and R.D. Toto Resistant hypertension: diagnosis, evaluation, and treatment: a statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
2. N. Chapman, J. Dobson, S. Wilson, B. Dahlöf, P.S. Sever, and H. Wedel Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 2007 839 845
3. J. Segura, C. Cerezo, J.A. Garcia-Donaire, R. Schmieder, M. Praga, and A. de la Sierra Validation of a therapeutic scheme for the treatment of resistant hypertension J Am Soc Hypertens 5 2011 498 504
4. H. Shibata, and H. Itoh Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension Am J Hypertens 25 2012 514 523
5. P. Raheja, A. Price, Z. Wang, D. Arbique, B. Adams-Huet, R.J. Auchus, and W. Vongpatanasin Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients Hypertension 60 2012 319 325
6. A. Pimenta, K.K. Gaddam, S. Oparil, I. Aban, S. Husain, and L.J. DellÍtalia Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension Hypertension 54 2009 475 481
7. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, and G.F. Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 2009 542 551
8. L. Shavit, M.D. Lifschitz, and M. Epstein Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms Kidney Int 81 2012 955 968
9. G. Parati, and M. Esler The human sympathetic nervous system: its relevance in hypertension and heart failure Eur Heart J 33 2012 1058 1066
10. S.J. Mann, and B.A. Parikh A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study J Clin Hypertens 14 2012 191 197
11. H. Krum, M. Schalaich, R. Whitbourn, P.A. Sobotka, J. Sadowski, and K. Bartus Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-concept cohort study Lancet 373 2009 1275 1281
12. SIMPLICITY HTN-2 Investigators Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial.): a randomised controlled trial Lancet 376 2010 1903 1909
13. SIMPLICITY HTN-1 Investigators Catheter based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months Hypertension 57 2011 911 917
14. A. Persu, J. Renkin, L. Thijs, and J. Staessen Renal denervation. Ultima ratio or standard in treatment-resistant hypertension Hypertension 60 2012 596 606
15. R.E. Schmieder, J. Redon, G. Grassi, J.E. Kjeldsen, G. Mancia, and K. Narkiewicz ESH position paper: renal denervation - an interventional therapy of resistant hypertension J Hypertens 30 2012 837 841
16. D.E. Kandzari, D.L. Bhatt, P.A. Sobotka, W.W. O'Neill, M. Esler, and J.M. Flack Catheter-based renal denervation for resistant hypertension: rationale and design of the SIMPLICITY HTN-3 trial Clin Cardiol 35 2012 528 535
17. C.B. Toal, P.A. Meredith, and H.L. Elliott Long-acting dihydropyridine calcium cannel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS Blood Press Suppl 21 2012 3 10
18. B. Geisler, B. Egan, J. Cohen, A.M. Garner, R.L. Akehurst, and M.D. Esler Cost-effectiveness of catheter-based renal denervation for resistant hypertension J Am Coll Cardiol 60 2012 1271 1277
19. A. Witkowski, Prejbisz, E. Florczak, J. Kadziela, P. Sliwinski, and P. Bielen Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea Hypertension 58 2011 559 565
20. M.C. Brandt, F. Mahfoud, S. Reda, S.H. Schirmer, E. Erdmann, and M. Böhm Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension J Am Col Cardiol 59 2012 901 909
21. F. Mahfoud, B. Cremers, J. Janker, B. Link, O. Vonend, and C. Ukena Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension Hypertension 60 2012 419 424
22. D. Hering, F. Mahfoud, A.S. Walton, H. Krum, G.W. Lambert, and E.A. Lambert Renal denervation in moderate to severe CKD J Am Soc Nephrol 23 2012 1250 1257